Scientific Advisory Panel on Bioequivalence Requirements for Modified-Release Dosage Forms - Membership List and Biographies

Membership List and Biographies

Related Information: The Summary of Expertise, Experience and Affiliations and Interests for the Scientific Advisory Panel on Bioequivalence Requirements for Modified Release Dosage Forms (SAP-MRDF) accompanies the member biographies. It summarizes the information provided by each member regarding their expertise/experience, and their affiliations and interests, which is required as part of the nominations process.

Jake Thiessen, PhD (Chair)

Hallman Director, School of Pharmacy
Director, Health Sciences Campus, University of Waterloo
Waterloo, Ontario


Jake Thiessen is the founding and current Director of both the School of Pharmacy and Health Sciences Campus at the University of Waterloo. Furthermore, he was the former Professor and Associate Dean at the Leslie Dan Faculty of Pharmacy, University of Toronto. He earned his BSc (Pharm) degree from the University of Manitoba, and went on to complete an MSc at Manitoba and a PhD at the University of California, San Francisco. His area of particular specialization is time-dependent processes defining drug fate in the body (pharmacokinetics) and drug response (pharmacodynamics). His research interests have included new approaches in cancer treatment and new molecules to treat patients with iron overload. Most recently, his studies have explored new applications of terahertz technology in the pharmaceutical and medical fields. His broader non-academic experience and expertise has come particularly from work with government agencies. Notable among these are the Drug Quality and Therapeutics Committee of the Ontario Ministry of Health, the Ministry of Health and Long Term Care (MOHLTC) Pharmacy Council, and Health Canada's Scientific Advisory Committee on Bioavailability and Bioequivalence.

Robert Herman, MD, FRCPC

Head, Division of General Internal Medicine, Health Sciences Centre
University of Calgary
Calgary, Alberta


Robert Herman obtained his MD from the University of Saskatchewan in 1977, and his license in Internal Medicine in 1981. He has a certificate in Clinical Pharmacology, obtained from Vanderbilt Medical University, Nashville, TN in 1983. He is currently Professor and Head of the Division of General Internal Medicine, Department of Medicine, University of Calgary. He is also the Clinical Chief of the Division of General Internal Medicine for Alberta Health Services, Calgary Zone. Prior to this appointment, he was a Professor in Medicine and Pharmacology at the University of Saskatchewan. Research/clinical interests include clinical pharmacology, drug metabolism and disposition, bioequivalence, drug interactions, hypertension, diabetes, hyperlipidemia, weight management, and smoking cessation. He is responsible for recruitment, and for design and delivery of Internal Medicine inpatient and outpatient services in Calgary. He has also had a major role in building a successful International Medical Graduate (IMG) Program and the movement of top level candidates into the Internal Medicine Training Program at that Centre. However, his true passions are caring for sick patients with complex medical problems and teaching as he attends on the Medical Teams and Internal Medicine Consult services at all three Calgary acute care hospitals.

Eugenia Palylyk-Colwell, BSc. Pharm., PhD

Consultant, Pharmacokinetics
Edmonton, Alberta


Eugenia Palylyk-Colwell completed her BSc Pharmacy (with Distinction) and PhD in Pharmaceutical Sciences (Pharmacokinetics) at the University of Alberta. She holds an Adjunct Academic appointment with the Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta and has many years of experience with Canadian provincial drug review processes and bioequivalence/interchangeability. She is a present or past member of various scientific organizations, has sat on many committees, advisory panels and working groups and is a core member of the Health Canada Scientific Advisory Committee on Bioavailability and Bioequivalence. She currently works as an independent consultant providing scientific, clinical review, and biomedical communication services to government, not-for-profit and private sector clients.

John D. Parker, MD, FRCPC

Professor of Medicine and Pharmacology, University of Toronto
Head, Division of Cardiology, Mount Sinai Hospital
Toronto, Ontario


John Parker obtained his medical degree from Queen's University in Kingston, Ontario in 1984. He completed 5 years of clinical and research training in cardiovascular medicine at the Brigham and Woman's Hospital in Boston. He returned to Toronto in 1992 to take up a faculty position as Assistant Professor of Medicine at the University of Toronto. At the present time, he holds the rank of Professor of Medicine and Pharmacology at the University of Toronto, and is head of the Department of Medicine of the University Health Network (Mount Sinai Hospital). His major interest is in clinical research with a focus on clinical pharmacology and autonomic physiology in heart failure.

Philippe Robaey, MD, PhD, FRCPC

Professor of Psychiatry, University of Ottawa
Research Director, Department of Psychiatry, Children's Hospital of Eastern Ontario
Ottawa, Ontario


Philippe Robaey is a full professor in the Department of Psychiatry and cross-appointed professor in the School of Psychology at the University of Ottawa. He has also obtained the National Researcher Career Award from the Fonds de la Recherche en Santé du Québec and is cross-appointed professor at the Université de Montréal. He obtained his MD at Free University at Brussels and his speciality in neuropsychiatry at the Catholic University of Leuven, a PhD in Health Sciences (psychophysiology) at the Université Paris 6. After his postdoctoral studies at the Unité de Recherche en Psychophysiologie Cognitive, Pathologie Psychiatrique et Neurologique, Unité de recherche 654, C.N.R.S. in the Pitié-Salpêtrière Hospital. He then continued his research and his innovative clinical endeavours at the Children Hospital of Eastern Ontario (CHEO) and the Institute of Mental Health Research (IMHR). He is an internationally recognized expert in Attention Deficit Hyperactivity Disorder (ADHD) and head of the specialized clinic for ADHD and disruptive behaviour at CHEO. He is also a specialist in mental health outcome of children treated for chronic diseases (leukemia, congenital disorders, prematurity, etc.) He is author of over 50 papers and as delivered over 200 national and international lectures. He also created an option in psychiatric sciences (master and PhD level) in the program of biomedical sciences at the faculty of medicine (Université de Montréal), and developed innovative courses in psychiatry. He is a member of the Society for Psychophysiological Research and the Canadian Academy of Child and Adolescent Psychiatry and on the editorial journal of this association.

Daniel Sitar, PhD

Professor, Departments of Pharmacology and Therapeutics and Internal Medicine
Clinical Pharmacology Section, University of Manitoba
Winnipeg, Manitoba


Daniel Sitar is Professor Emeritus (University of Manitoba, January 2010). He is Editor of the Journal of Clinical Pharmacology (2009 - present). Academic associations include the Departments of Internal Medicine (Clinical Pharmacology Section), Pharmacology and Therapeutics, and Paediatrics and Child Health (Faculty of Medicine), and Faculty of Pharmacy. He received his BSc Pharm (1966), MSc (1968) in Pharmacy, and PhD (1972) in Pharmacology, all from the University of Manitoba. He holds Fellowship status in American College of Clinical Pharmacology, and in the Gerontological Society of America (Health Sciences). He also serves on the Editorial Board of Clinical Pharmacology and Therapeutics (1986 - present).

Page details

Date modified: